MM 77 dihydrochloride
A highly potent and fairly selective 5-HT1A ligand, which may be a full antagonist at postsynaptic receptors.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 418.36. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.39 mL||11.95 mL||23.9 mL|
|5 mM||0.48 mL||2.39 mL||4.78 mL|
|10 mM||0.24 mL||1.2 mL||2.39 mL|
|50 mM||0.05 mL||0.24 mL||0.48 mL|
References are publications that support the products' biological activity.
If you know of a relevant reference for MM 77 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: MM 77 dihydrochloride, supplier, 5-HT1A, postsynaptic, antagonists, Serotonin, Receptors, MM77, dihydrochloride, 5-HT1A, Receptors, 5-HT1A, Receptors, Tocris Bioscience
Citations for MM 77 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for MM 77 dihydrochloride. Do you know of a great paper that uses MM 77 dihydrochloride from Tocris? If so please let us know.
MM 77 dihydrochloride Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.